Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma

26 August 2026 · By · Wire by Fusion42

Published

26 August 2026

Topic

opportunities

◆ Sectors

Drug Discovery

◆ Geography

United States

◆ Source

Read at onclive.com →

◆ Verified

Fusion42 · 26 August 2026 · Fusion42 review

The US FDA has approved daraxonrasib for the treatment of metastatic pancreatic ductal adenocarcinoma based on positive results from the phase 3 RASolute 302 trial.

This Wire brief sits within Fusion42's coverage of Drug Discovery, and 48 sources have reported it between 26 Aug 2026 and 16 Oct 2026.

◆ ◆ The Wire takeaway

This FDA approval opens a new market for pancreatic cancer treatments. You working on oncology drug discovery must move fast to explore combination therapies with daraxonrasib or face losing early adopter oncology centres.

◆ Coverage

48 sources · first reported 26 Aug 2026 · latest 16 Oct 2026

◆ Related on Wire

◆ Topics

Drug Discoveryfda-approvalpancreatic-cancerdaraxonrasiboncologyphase-3-trial